Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797616 | 1.00 | GABRA5 (0.51) | GABRA5GABRA1ITGA5 | |
| SCHEMBL7800791 | 1.00 | GABRA5 (0.51) | GABRA5GABRA1ITGA5 | |
| SCHEMBL15252233 | 0.88 | GABRA5 (0.46) | GABRA5GABRA1ITGA5 | |
| SCHEMBL15252509 | 0.88 | GABRA5 (0.46) | GABRA5GABRA1ITGA5 | |
| SCHEMBL15252352 | 0.88 | GABRA5 (0.46) | GABRA5GABRA1ITGA5 | |
| SCHEMBL7797621 | 0.86 | GABRA5 (0.48) | GABRA5GABRA1ITGA5 | |
| SCHEMBL286058 | 0.86 | GABRA1 (0.48) | GABRA5GABRA1ITGA5 | |
| SCHEMBL295695 | 0.86 | GABRA1 (0.48) | GABRA5GABRA1ITGA5 | |
| SCHEMBL300344 | 0.86 | GABRA1 (0.48) | GABRA5GABRA1ITGA5 | |
| SCHEMBL285417 | 0.86 | GABRA5 (0.69) | GABRA5GABRA1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398782-B1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8173652-B2 | Isoxazole-isoxazoles and isoxazole-isothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173652-B2 | Isoxazole-isoxazoles and isoxazole-isothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010094669-A1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885ITGA5 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.